These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 10821360)

  • 1. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
    Flather MD; Yusuf S; Køber L; Pfeffer M; Hall A; Murray G; Torp-Pedersen C; Ball S; Pogue J; Moyé L; Braunwald E
    Lancet; 2000 May; 355(9215):1575-81. PubMed ID: 10821360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
    Teo KK; Yusuf S; Pfeffer M; Torp-Pedersen C; Kober L; Hall A; Pogue J; Latini R; Collins R;
    Lancet; 2002 Oct; 360(9339):1037-43. PubMed ID: 12383982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
    Sigurdsson A; Swedberg K
    Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
    Garg R; Yusuf S
    JAMA; 1995 May; 273(18):1450-6. PubMed ID: 7654275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function.
    Frances CD; Noguchi H; Massie BM; Browner WS; McClellan M
    Arch Intern Med; 2000 Sep; 160(17):2645-50. PubMed ID: 10999979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.
    Nakata T; Wakabayashi T; Kyuma M; Takahashi T; Tsuchihashi K; Shimamoto K
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):186-94. PubMed ID: 15452671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
    Voors AA; de Kam PJ; van den Berg MP; Borghi C; Hochman JS; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):119-24. PubMed ID: 16025230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
    Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
    Peterson JG; Topol EJ; Sapp SK; Young JB; Lincoff AM; Lauer MS
    Am J Med; 2000 Oct; 109(5):371-7. PubMed ID: 11020393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB
    Cardiol Clin; 1995 Aug; 13(3):379-90. PubMed ID: 7585774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
    Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
    N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.